Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Core Insights - Achieve Life Sciences, Inc. has approved stock option grants for five new employees as part of its 2024 Equity Inducement Plan, totaling 161,000 shares of common stock [1][2][3] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence treatment [4] - The company submitted a New Drug Application (NDA) to the FDA in June 2025, which has been accepted for review, with a PDUFA date set for June 20, 2026 [4] - Cytisinicline is being developed for smoking cessation in adults, supported by two completed Phase 3 studies and an open-label safety study [4] Industry Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death globally [5] - There are around 17 million adults in the U.S. who use e-cigarettes, highlighting a significant market for cessation products [5] - Cytisinicline has received Breakthrough Therapy designation from the FDA to address the unmet need for e-cigarette cessation treatments [5][6]